Charles Taylor
Endocrinology, Diabetes & Metabolism · Farmington Hills, MINPI 1952348948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,470 and has fallen 98.7% since, to $19 in 2025.
Across 285 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$758
- Amgen$654
- Lilly USA, LLC$446
- Merck$273
- AbbVie$222
- AstraZeneca$195
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,368100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $758 |
| Amgen(2 entities) | 48 | $654 |
| Lilly USA, LLC | 25 | $446 |
| Merck | 22 | $273 |
| AbbVie(2 entities) | 12 | $222 |
| AstraZeneca(2 entities) | 13 | $195 |
| Abbott | 9 | $146 |
| Amneal Pharmaceuticals LLC | 9 | $143 |
| Mannkind Corporation | 9 | $130 |
| Johnson & Johnson | 8 | $110 |
| Dexcom, Inc. | 6 | $108 |
| Insulet Corporation | 4 | $75 |
| Radius Health, Inc. | 4 | $73 |
| Bayer | 3 | $72 |
| Pfizer | 5 | $67 |
| Amryt Pharma Holdings Ltd | 4 | $60 |
| Boehringer Ingelheim | 4 | $60 |
| Antares Pharma, Inc. | 3 | $59 |
| Nevro Corp. | 1 | $59 |
| Ipsen Biopharmaceuticals, Inc | 3 | $57 |
| Shire North American Group Inc | 4 | $54 |
| Recordati_rare_diseases_inc. | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Alvogen Inc | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| IBSA Pharma Inc. | 3 | $40 |
| Amarin Pharma, Inc. | 3 | $38 |
| BD | 2 | $37 |
| EUSA Pharma (US) LLC | 2 | $35 |
| Corcept Therapeutics | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Companion Medical, Inc. | 1 | $21 |
| Gilead | 1 | $16 |
| Valeritas, Inc. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Lifescan, Inc. | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,368 in reported general payments places this provider in the 65th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Other endocrinology, diabetes & metabolism in Farmington Hills
- Lowell SchmeltzFarmington Hills$1.3M
- Gary EdelsonFarmington Hills$503K
- Jacob MoeFarmington Hills$7K
- George GrunbergerBloomfield Hills$931K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.